Estimates of Single Dose and Full Dose BNT162b2 Vaccine Effectiveness among USAF Academy cadets, 1 Mar - 1 May 2021
Wickert, D. P.; Almand, E.; Cullenbine, C. A.; Huckstep, O. J.; Rohrer, J.; Sitko, J. C.; Steel, J. J.; Hasstedt, S.
Show abstract
Beginning in early March 2021 and continuing through May 2021, the USAF Academy began vaccinating cadets for protection against the SARS-CoV-2 virus with the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. During this period, vaccination of the almost 4200 cadet population increased from 3% to 85% and prevalence of COVID-19 in the cadet population was constant at approximately 0.4% as indicated by weekly surveillance testing. In this study, vaccine effectiveness at preventing infection is estimated by comparing infection risk as a function of time since vaccination. A statistically significant four-fold reduction in infection risk was observed 14 days after the first vaccine dose and an eleven-fold reduction in infection risk was observed in fully vaccinated cadets. Overall, the Pfizer-BioNTech vaccine was 91% (95% confidence interval = 55-99%) effective at preventing infection in healthy young adults (17-26 years of age) in a university setting and military training environment.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults 96%
- Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine 95%
- Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study 95%
Similar papers in this journal
- Benefit-Risk Assessment Of COVID-19 Vaccine, Mrna (Mrna-1273) For Males Age 18-64 Years 94%
- Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers 94%
- Psychosocial factors affecting COVID-19 vaccine uptake in the UK: a prospective cohort study (CoVAccS – wave 3) 93%
Similar papers in this journal
- Safety and immunogenicity of the BBIBP-CorV vaccine in adolescents aged 12-17 years in Thai population, prospective cohort study 96%
- Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine 96%
- Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222 95%
Similar papers in this journal
- Risk of Coronavirus Disease 2019 (COVID-19) among Those Up-to-Date and Not Up-to-Date on COVID-19 Vaccination 95%
- Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States—January–April, 2021 95%
- Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study 95%
Similar papers in this journal
- Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine 96%
- Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study 95%
- Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.